亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

医学 临床终点 内科学 养生 胃肠病学 腺癌 临床研究阶段 奥沙利铂 叶酸 癌症 肿瘤科 化疗 外科 临床试验 氟尿嘧啶 结直肠癌
作者
Kohei Shitara,Florian Lordick,Yung‐Jue Bang,Peter C. Enzinger,David H. Ilson,Manish A. Shah,Eric Van Cutsem,Rui‐Hua Xu,Giuseppe Aprile,Jianming Xu,Joseph Chao,Roberto Pazo-Cid,Yoon‐Koo Kang,Jianning Yang,Diarmuid M. Moran,Pranob Bhattacharya,Ahsan M. Arozullah,Jung Wook Park,Mok Oh,Jaffer A. Ajani
出处
期刊:The Lancet [Elsevier]
卷期号:401 (10389): 1655-1668 被引量:247
标识
DOI:10.1016/s0140-6736(23)00620-7
摘要

Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.2), has shown efficacy in patients with CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. We report the results of the SPOTLIGHT trial, which investigated the efficacy and safety of first-line zolbetuximab plus mFOLFOX6 (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen) versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.SPOTLIGHT is a global, randomised, placebo-controlled, double-blind, phase 3 trial that enrolled patients from 215 centres in 20 countries. Eligible patients were aged 18 years or older with CLDN18.2-positive (defined as ≥75% of tumour cells showing moderate-to-strong membranous CLDN18 staining), HER2-negative (based on local or central evaluation), previously untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with radiologically evaluable disease (measurable or non-measurable) according to Response Evaluation Criteria in Solid Tumors version 1.1; an Eastern Cooperative Oncology Group performance status score of 0 or 1; and adequate organ function. Patients were randomly assigned (1:1) via interactive response technology and stratified according to region, number of organs with metastases, and previous gastrectomy. Patients received zolbetuximab (800 mg/m2 loading dose followed by 600 mg/m2 every 3 weeks) plus mFOLFOX6 (every 2 weeks) or placebo plus mFOLFOX6. The primary endpoint was progression-free survival assessed by independent review committee in all randomly assigned patients. Safety was assessed in all treated patients. The study is registered with ClinicalTrials.gov, NCT03504397, and is closed to new participants.Between June 21, 2018, and April 1, 2022, 565 patients were randomly assigned to receive either zolbetuximab plus mFOLFOX6 (283 patients; the zolbetuximab group) or placebo plus mFOLFOX6 (282 patients; the placebo group). At least one dose of treatment was administered to 279 (99%) of 283 patients in the zolbetuximab group and 278 (99%) of 282 patients in the placebo group. In the zolbetuximab group, 176 (62%) patients were male and 107 (38%) were female. In the placebo group, 175 (62%) patients were male and 107 (38%) were female. The median follow-up duration for progression-free survival was 12·94 months in the zolbetuximab group versus 12·65 months in the placebo group. Zolbetuximab treatment showed a significant reduction in the risk of disease progression or death compared with placebo (hazard ratio [HR] 0·75, 95% CI 0·60-0·94; p=0·0066). The median progression-free survival was 10·61 months (95% CI 8·90-12·48) in the zolbetuximab group versus 8·67 months (8·21-10·28) in the placebo group. Zolbetuximab treatment also showed a significant reduction in the risk of death versus placebo (HR 0·75, 95% CI 0·60-0·94; p=0·0053). Treatment-emergent grade 3 or worse adverse events occurred in 242 (87%) of 279 patients in the zolbetuximab group versus 216 (78%) of 278 patients in the placebo group. The most common grade 3 or worse adverse events were nausea, vomiting, and decreased appetite. Treatment-related deaths occurred in five (2%) patients in the zolbetuximab group versus four (1%) patients in the placebo group. No new safety signals were identified.Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients.Astellas Pharma, Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云应助yamo采纳,获得30
9秒前
25秒前
nuki完成签到 ,获得积分10
29秒前
FashionBoy应助阿宇采纳,获得10
32秒前
蒋田姣完成签到 ,获得积分10
51秒前
52秒前
锋芒不毕露完成签到,获得积分10
53秒前
大个应助XL神放采纳,获得20
1分钟前
隔壁小黄完成签到 ,获得积分10
1分钟前
wan完成签到 ,获得积分10
1分钟前
科研通AI2S应助司徒无剑采纳,获得10
2分钟前
2分钟前
Yang发布了新的文献求助10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
大模型应助科研通管家采纳,获得10
2分钟前
2分钟前
董小妍完成签到 ,获得积分10
2分钟前
朱可芯完成签到,获得积分20
2分钟前
朱可芯发布了新的文献求助10
2分钟前
Singularity应助朱可芯采纳,获得10
2分钟前
科研通AI2S应助Yang采纳,获得10
2分钟前
3分钟前
Yang完成签到,获得积分10
3分钟前
阿治完成签到 ,获得积分10
3分钟前
轻松的采柳完成签到 ,获得积分10
3分钟前
3分钟前
咯咯咯发布了新的文献求助20
3分钟前
3分钟前
3分钟前
领导范儿应助走下班了采纳,获得10
3分钟前
3分钟前
yamo发布了新的文献求助30
3分钟前
3分钟前
SciGPT应助平淡的芷蕊采纳,获得10
3分钟前
4分钟前
XL神放发布了新的文献求助20
4分钟前
CodeCraft应助countingrabbit采纳,获得10
4分钟前
852应助三木采纳,获得10
4分钟前
封似狮完成签到,获得积分10
4分钟前
zzeru21发布了新的文献求助150
4分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
XAFS for Everyone (2nd Edition) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3133920
求助须知:如何正确求助?哪些是违规求助? 2784809
关于积分的说明 7768627
捐赠科研通 2440175
什么是DOI,文献DOI怎么找? 1297190
科研通“疑难数据库(出版商)”最低求助积分说明 624911
版权声明 600791